TheJobsMapUvax Bio jobs and careers
Newark, DE, United States
About Uvax Bio
Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world. Our 1c-SApNP technology streamlines vaccine development and has delivered promising vaccine candidates to address global health challenges such as HIV, RSV/hMPV, PIV1-5, Ebola/Marburg, Lassa, coronaviruses including SARS-CoV, MERS-CoV and SARS-CoV-2, HCV, ZIKV/DENV, and non-viral diseases such as Malaria and Tuberculosis.
Founded in 2018 by Ji Li and Jiang Zhu.
- Founded
- 2018
- Employees
- 11 to 50
- Total funding
- $20M
- Headquarters
- Newark
Leadership
The top of Uvax Bio's org chart, with how many people report into each leader.
Kevin O'neill
Chief Executive Officer
3 reports
Ke Li
Vice President, Vaccine Development and Technical Ops
2 reports
Matthijs Schoots
Chief of Staff, Head Strategic Planning
Pedro Garbes
Vice President, Global Medical Lead
Keegan Braz Gomes
Director, Preclinical Research
Xiong Liu
Associate Director, VDPM
Mary Giffear
Senior Director, Global Clincal Operations
Jobs at Uvax Bio
No open positions right now. Explore more companies on TheJobsMap.